Spekar Therapeutics is a specialty pharmaceutical company focused on licensing, developing and commercializing value-added formulations in the central nervous system space.

We optimize established molecules by reformulating or repositioning them towards new indications with improved clinical benefits. Our goal is to provide patients with products that offer better safety, efficacy and convenience over existing treatments while delivering them in a cost-effective manner.

Spektar utilizes an asset light business model that leverages a wide network of third-party research and manufacturing partners to develop our proprietary formulations. We partner with leading pharmaceutical companies to ensure our products are delivered to patients across the globe with the best standards of quality and compliance.

We are constantly on the lookout for new technologies and partners that can help expand our portfolio or deliver them to a broader range of patients.

Spektar works with partners across the following areas of the pharmaceutical value chain:

• Non-clinical and clinical researchers
• Formulation development partners
• API manufacturing suppliers
• Finished goods contract manufacturers
• Commercial and marketing organizations